2021
The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology 2021, 33: 75-83. PMID: 34669631, PMCID: PMC8633045, DOI: 10.1097/ede.0000000000001418.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh positive predictive valueFuture tuberculosisLatent tuberculosis infection treatmentIncremental costHigher treatment initiationCompletion of treatmentInterferon-gamma releaseQuality-adjusted life yearsTransmission dynamic modelLTBI testingTreatment initiationTreatment acceptanceTuberculosis diseasePrevention servicesPredictive valueTreatment servicesLife yearsTuberculosisInfection treatmentSocietal perspectiveIGRATreatment volumeHealth improvementFuture progressionDevelopment of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis
Gunasekera KS, Walters E, van der Zalm MM, Palmer M, Warren JL, Hesseling AC, Cohen T, Seddon JA. Development of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis. Clinical Infectious Diseases 2021, 73: e904-e912. PMID: 33449999, PMCID: PMC8366829, DOI: 10.1093/cid/ciab018.Peer-Reviewed Original ResearchConceptsPulmonary tuberculosisClinical evidenceXpert MTB/RIFBaseline clinical evaluationChest radiographic resultsRapid treatment initiationNational Tuberculosis ProgrammeTreatment decision algorithmsEvidence-based algorithmMTB/RIFDiagnosis of tuberculosisChest radiographicAntituberculosis treatmentProspective cohortRadiographic resultsTreatment initiationTuberculosis casesTuberculosis ProgrammeClinical evaluationCase definitionTreatment decisionsGlobal burdenChildhood mortalityChildren EvaluatedRapid clinical diagnosis
2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen